by | Oct 24, 2024 | Uncategorized
The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.The combination reduced risk for disease progression or death by 47% compared with...
by | Oct 23, 2024 | Uncategorized
A new initiative to rapidly place individuals with acute myeloid leukemia or myelodysplastic syndrome in clinical trials based on their genomic profiles has opened in the United States and Canada.The myeloMATCH program will enroll patients into different studies as...
by | Oct 14, 2024 | Uncategorized
A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.Nearly all patients with multiple myeloma eventually relapse. CAR...
by | Oct 9, 2024 | Uncategorized
Source: CureToday articles Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse. Read More
by | Oct 5, 2024 | Uncategorized
Source: CureToday articles The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant. Read More
by | Oct 3, 2024 | Uncategorized
Source: CureToday articles Reflecting on the pain I experienced before my diagnosis of multiple myeloma, I realized how important it was to pay attention to the related symptoms. Read More
